Abstract
To reveal the pathomechanisms of glaucoma, a common cause of blindness, suitable animal models are needed. As previously shown, retinal ganglion cell and optic nerve degeneration occur in βB1-CTGF mice. Here, we aimed to determine possible apoptotic mechanisms and degeneration of different retinal cells. Hence, retinae were processed for immunohistology (n = 5–9/group) and quantitative real-time PCR analysis (n = 5–7/group) in 5- and 10-week-old βB1-CTGF and wildtype controls. We noted significantly more cleaved caspase 3+ cells in βB1-CTGF retinae at 5 (p = 0.005) and 10 weeks (p = 0.02), and a significant upregulation of Casp3 and Bax/Bcl2 mRNA levels (p < 0.05). Furthermore, more terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL+) cells were detected in transgenic mice at 5 (p = 0.03) and 10 weeks (p = 0.02). Neurofilament H staining (p = 0.01) as well as Nefh (p = 0.02) and Tubb3 (p = 0.009) mRNA levels were significantly decreased at 10 weeks. GABAergic synapse intensity was lower at 5 weeks, while no alterations were noted at 10 weeks. The glutamatergic synapse intensity was decreased at 5 (p = 0.007) and 10 weeks (p = 0.01). No changes were observed for bipolar cells, photoreceptors, and macroglia. We conclude that apoptotic processes and synapse loss precede neuronal death in this model. This slow progression rate makes the βB1-CTGF mice a suitable model to study primary open-angle glaucoma.
Keywords: βB1-CTGF, primary open-angle glaucoma, apoptosis, caspase 3, neurofilament H, Bax/Bcl2, synapse
1. Introduction
Glaucoma is a leading cause of blindness worldwide [1]. It is a chronic, progressive neuropathy in which apoptosis of retinal ganglion cells (RGCs) and loss of optic nerve axons result in structural and functional deficits, such as visual field loss [2,3]. The main and currently only modifiable risk factor is the high intraocular pressure (IOP). At present, the only treatment with evidence in preserving visual function is the reduction in IOP [3,4,5]. This is associated with reduced disease progression but is not able to revert damage [6]. This poses a problem, since glaucoma is often diagnosed at advanced stages, when about 30% of RGCs are already lost [4]. Therefore, allowing for diagnoses at earlier stages could have a substantial impact on the glaucoma therapy. To develop new diagnosis tools as well as novel therapy options, a reliable animal model for primary open-angle glaucoma (POAG) is necessary. In POAG, the increased IOP is caused by a high resistance to aqueous humor outflow in the trabecular meshwork [7,8]. The transgenic glaucoma model of the connective tissue growth factor (βB1-CTGF) mouse simulates these pathomechanisms without any surgical interventions. In this model, the lens-specific overexpression of CTGF in mice is responsible for changes in the cytoskeleton and the extracellular matrix in the trabecular meshwork. In 2012, Junglas et al. demonstrated that 4-week-old βB1-CTGF mice with a FVB/NxCD1 background develop an elevated IOP accompanied by a loss of optic nerve axons [7]. To investigate whether glaucoma-like damage also occurs in the retinae of these animals, we performed in vivo and in vitro analyses of βB1-CTGF mice. The animals in our study were backcrossed and had a CD1 background, since it is known that this strain is more susceptible to IOP changes [9,10]. The transgenic mice developed a significantly increased IOP at 15 weeks of age, while at 5 and 10 weeks, the IOP remained unaltered. In addition, we could note a loss of retinal function, a decline in RGC and cone bipolar cell numbers, as well as reactive macroglia at the age of 15 weeks. Different time courses between both studies could be explained by using different background strains [11]. Nonetheless, little is known about the early retinal changes in βB1-CTGF mice. Therefore, further characterization of this model is needed.
The aim of this study is to investigate possible apoptotic processes and changes in retinal cells and synapses. We show early apoptosis starting in 5-week-old transgenic mice, leading to a loss of neurofilament H at 10 weeks of age. This was accompanied by a loss of glutamatergic synapses in transgenic animals.
2. Results
2.1. Loss of Neurofilament H at 10 Weeks
In order to analyze the number of RGCs in 5- and 10-week-old βB1-CTGF mice, immunohistological staining with antibodies against Brn3a and neurofilament H was performed (Figure 1A). We could see a comparable total number of Brn-3a+ cells in 5-week-old βB1-CTGF (108.18 ± 6.24%) and wildtype (WT) mice (100.00 ± 4.81%; p = 0.32). At 10 weeks of age, the βB1-CTGF (84.51 ± 6.00%) and the WT groups (100.00 ± 11.42%; p = 0.25) revealed similar RGC counts (Figure 1B). The RGC number in the central part of the retina was comparable in 5-week-old βB1-CTGF (103.27 ± 5.93%) and WT animals (100.00 ± 6.03%; p = 0.28). This could also be noted at 10 weeks (WT: 100.00 ± 10.58%; βB1-CTGF: 82.64 ± 7.63%; p = 0.20; Figure 1B). In the peripheral parts, the number of Brn3a+ RGCs did not differ between transgenic (116.08 ± 9.85%) and WT mice (100.00 ± 10.15%; p = 0.71) at 5 weeks. In addition, at 10 weeks, similar RGC counts were detected in βB1-CTGF (85.24 ± 5.33%) and WT animals (100.00 ± 12.91%; p = 0.31; Figure 1B).
Furthermore, the RT-qPCR analyses showed similar mRNA expression levels of the RGC marker Pou4f1 in βB1-CTGF mice compared to in WT mice at 5 (1.02-fold expression; p = 0.09) and 10 weeks (1.04-fold expression; p = 0.75; Figure 1C).
Regarding Tubb3 mRNA levels, a neuronal marker, no alterations were noted between βB1-CTGF and WT mice (1.08-fold expression; p = 0.86) at 5 weeks. 10-week-old transgenic animals already had significantly downregulated Tubb3 mRNA levels (0.67-fold expression; p = 0.009; Figure 1D).
Regarding neurofilament H, at 5 weeks, the stained area was comparable in βB1-CTGF (79.64 ± 12.08%) and WT animals (100.00 ± 8.92%; p = 0.2; Figure 1E). Then, a significant decrease in the neurofilament H+ area was revealed in transgenic mice (60.42 ± 5.92%) compared to in WT ones (100.00 ± 11.25%; p = 0.01) at 10 weeks of age (Figure 1E).
No alterations in the expression levels of Nefh could be noted between βB1-CTGF and WT mice at 5 weeks (1.68-fold expression; p = 0.15). However, in accordance with the immunohistological findings, a significant downregulation of Nefh mRNA was observed in 10-week-old transgenic animals (0.69-fold expression; p = 0.02; Figure 1F).
These results reveal a loss of neurofilament H in βB1-CTGF mice at the age of 10 weeks.
2.2. Increased Number of Apoptotic Retinal Ganglion Cells
To detect possible apoptosis of RGCs, retinal cross sections were co-stained with an anti-cleaved caspase 3 antibody and anti-Brn3a (Figure 2A). At 5 weeks of age, we already noted significantly more cleaved caspase 3+ RGCs in βB1-CTGF mice (38.81 ± 4.58 cells/mm) compared to in WT mice (20.47 ± 2.76 cell/mm; p = 0.005). We still observed significantly more cleaved caspase 3+ RGCs in βB1-CTGF retinae (36.26 ± 3.53 cells/mm) compared to in WT retinae (22.29 ± 3.85 cells/mm; p = 0.02) at 10 weeks (Figure 2B).
Additionally, the mRNA expression levels of Casp3 were significantly increased in transgenic mice at 5 (2.06-fold expression; p = 0.02) and 10 weeks of age (1.45-fold expression; p = 0.03; Figure 2C). This is in agreement with the immunohistological data.
Furthermore, we analyzed the expression levels of Bax/Bcl2 mRNA. At 5 weeks, the mRNA levels of Bax/Bcl2 were comparable between βB1-CTGF and WT mice (0.97-fold expression; p = 0.9). Then, a significant upregulation of Bax/Bcl2 mRNA was noted in 10-week-old transgenic mice (1.36-fold expression; p = 0.04, Figure 2D).
In addition, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining, an established method to detect DNA fragmentation, such as in apoptosis, was performed on retinal cross sections of βB1-CTGF and WT animals to further investigate cell death in this model (Figure 2A). A significantly higher number of TUNEL+ cells in the ganglion cell layer of βB1-CTGF mice was detected (4.02 ± 1.02 cells/mm) compared to that in WT ones (1.28 ± 0.40 cells/mm; p = 0.03) at 5 weeks. Also, at 10 weeks, an even higher number of TUNEL+ cells could be monitored in transgenic animals (2.70 ± 1.49 cells/mm) in comparison to WT mice (0.38 ± 0.38 cells/mm; p = 0.02; Figure 2E)
To summarize, apoptotic mechanisms are notable in 5-week-old βB1-CTGF mice and seem to play a major role in subsequent cell death.
2.3. Loss of Synapses
Alterations in synapses were detected by staining retinae with anti-gephyrin (GABAergic synapses) and anti-Vglut1 (glutamatergic synapses; Figure 3A). The gephyrin+ area was significantly decreased in βB1-CTGF animals (51.21 ± 11.42%) compared to in WT retinae (100.00 ± 14.78%; p = 0.02) at 5 weeks. At 10 weeks, no changes in the gephyrin+ area were noted in transgenic mice (115.22 ± 13.10%) when compared to in WT ones (100.00 ± 10.91%; p = 0.4; Figure 3B).
The Gphn mRNA analyses revealed no changes at 5 weeks (0.47-fold expression; p = 0.2). At 10 weeks, a significant downregulation of Gphn mRNA levels was noted in βB1-CTGF retinae (0.67-fold expression; p = 0.02; Figure 3C).
At 5 weeks, a significantly lower Vglut1 intensity was detectable in βB1-CTGF retinae (49.72 ± 6.22%) compared to in WT animals (100.00 ± 14.20%; p = 0.007). Also, at 10 weeks, a significant decrease in the Vglut1 intensity was seen in the βB1-CTGF mice (51.34 ± 8.71%) compared to in the WT ones (100.00 ± 14.50%; p = 0.01; Figure 3D).
The mRNA expression of Slc17a7 (encodes Vglut1 in mice) did not differ in βB1-CTGF retinae at 5 (0.8-fold expression; p = 0.7) and 10 weeks (0.9-fold expression; p = 0.3; Figure 3E).
Furthermore, ribbon synapses were visualized with an anti-ribeye antibody and co-stained with an antibody against PKCα (rod bipolar cells; Figure 3F). We could show co-staining of ribeye+ ribbon synapses and PKCα+ rod bipolar cells in both groups in the inner nuclear and outer plexiform layers. In WT animals at 5 and 10 weeks of age, co-staining of ribeye and PKCα was more intense compared to the corresponding βB1-CTGF mice. We assumed alterations in ribbon synapses at early stages in this transgenic mouse model.
These results suggest an early loss of synapses, before a significant cell loss can be observed in βB1-CTGF mice.
2.4. Similar Bipolar Cell Numbers
To evaluate the number of cone and rod bipolar cells, retinal cross sections were labeled with anti-PKCα (rod bipolar cells) and anti-recoverin (cone bipolar cells; Figure 4A). At 5 weeks, the cone bipolar cell number was similar in βB1-CTGF mice (103.09 ± 28.88%) and WT mice (100.00 ± 18.58%; p = 0.93). At 10 weeks, there were comparable recoverin+ cone bipolar cells in βB1-CTGF mice (67.39 ± 10.49%) compared to in WT mice (100.00 ± 11.15%; p = 0.052; Figure 4B).
The RT-qPCR analyses displayed similar Rcvrn mRNA levels in βB1-CTGF and WT animals at 5 (0.68-fold expression; p = 0.61) and 10 weeks (0.84-fold expression; p = 0.48; Figure 4C).
The number of rod bipolar cells was comparable between βB1-CTGF mice (78.56 ± 14.69%) and WT animals (100.00 ± 9.60%; p = 0.23) at 5 weeks. Additionally, at 10 weeks of age, no changes in the number of PKCα+ cells were detected in βB1-CTGF retinae (90.80 ± 7.66%) compared to in WT ones (100.00 ± 13.27%; p = 0.57; Figure 4D).
RT-qPCR analyses of Prkca mRNA showed no alterations in transgenic mice compared to in WT retinae at 5 (1.00-fold expression; p = 0.99) and 10 weeks of age (1.16-fold expression; p = 0.45; Figure 4E).
Additionally, the mRNA levels of Slc18a3 (encoding for the vesicular acetylcholine transporter) were not altered in 5- (0.89-fold expression; p = 0.79) and 10-week-old βB1-CTGF animals (1.13-fold expression; p = 0.59; Figure 4F).
In summary, cone and rod bipolar cells were not affected in 5- and 10-weeks-old transgenic mice compared to in WT ones.
2.5. No Effects on Photoreceptors
To analyze possible alterations in photoreceptors, the rods were labeled with anti-rhodopsin and L-cones with anti-opsin (Figure 5A). No significant difference in rods could be noted at 5 weeks of age (βB1-CTGF: 110.31 ± 17.21%; WT: 100.00 ± 15.26%; p = 0.66). At 10 weeks, the rhodopsin+ area remained unchanged in βB1-CTGF retinae (112.33 ± 9.09%) compared to in WT animals (100.00 ± 9.90%; p = 0.38; Figure 5).
This was confirmed by RT-qPCR analysis, where no significant downregulation of Rho mRNA levels was noted in βB1-CTGF animals at both points in time (5 weeks: 0.63-fold expression; p = 0.06; 10 weeks: 0.89-fold expression; p = 0.46; Figure 5C).
The number of L-cones was comparable in βB1-CTGF retinae (5 weeks: 92.68 ± 10.45%; 10 weeks: 95.30 ± 12.91%) and WT retinae (5 weeks: 100.00 ± 6.30%; p = 0.56; 10 weeks: 100.00 ± 14.36%; p = 0.81) at 5 and 10 weeks (Figure 5D).
These results indicate that photoreceptors are not affected in βB1-CTGF mice at 5 and 10 weeks of age.
2.6. No Alteration in Macroglia
To examine a possible macrogliosis, retinal cross sections were labeled with anti-GFAP and anti-glutamine synthetase (Figure 6A). Analysis of the GFAP+ area indicated a similar GFAP signal area in βB1-CTGF (130.88 ± 22.60%) and WT retinae (100.00 ± 18.35%; p = 0.31) at 5 weeks. Additionally, at 10 weeks, no alterations were noted in βB1-CTGF mice (142.47 ± 27.66%) compared to in WT (100.00 ± 27.99%; p = 0.30; Figure 6).
No significant difference between βB1-CTGF mice (5 weeks: 133.23 ± 21.25%; 10 weeks: 143.64 ± 29.27%) and WT mice (5 weeks: 100.00 ± 6.26%; p = 0.16; 10 weeks: 100.00 ± 28.66%; p = 0.30) could be detected with regard to glutamine synthetase+ signal area at both ages (Figure 6C).
In summary, at 5 and 10 weeks of age, no macroglia alterations could be observed in βB1-CTGF animals. Later, at 15 weeks, an increased macroglia activation was noted in transgenic mice [11].
2.7. No Functional or Morphological alterations
Electroretinogram (ERG) analyses were performed in 5- and 10-week-old animals. The recordings at a light intensity of 10 cd.s/m2 are pictured. The electrical output of the photoreceptors is represented by the a-wave amplitude. At 5 weeks, no difference between βB1-CTGF and WT mice could be noted at all light intensities (p > 0.05). At 10 weeks, the a-wave amplitude was also comparable between βB1-CTGF and WT mice at all light intensities (p > 0.05; Supplementary Figure S1A). The b-wave amplitude represents the electrical output of the inner nuclear layers. At all light intensities, we noted no significant change in the b-wave amplitude in βB1-CTGF mice compared to WT mice at 5 weeks and 10 weeks (p > 0.05; Supplementary Figure S1B).
To analyze the thickness of the retina, spectral domain ocular coherence tomographies (SD-OCTs) were performed in βB1-CTGF and WT animals at 5 and 10 weeks of age (Supplementary Figure S1C). The total retinal thickness was comparable between βB1-CTGF (92.42±8.34 %) and WT mice (100.00±2.02 %; p = 0.42) at 5 weeks. At 10 weeks, there was also no significant difference between βB1-CTGF (99.06±2.51 %) and WT retinae (100.00±2.13 %; p = 0.78) in the total thickness. No differences were noted regarding the central retinal thickness in 5-week-old animals (WT: 100.00±5.29 %; βB1-CTGF: 95.76±7.80 %; p = 0.67). Also, at 10 weeks, the central retinal thickness did not differ between transgenic (108.06±3.48 %) and WT mice (100.00±7.58 %; p = 0.40). Furthermore, measurements of the peripheral part of the retina showed no alterations at 5 (WT: 100.00±0.98 %; βB1-CTGF: 91.03±9.03%; p = 0.37) and 10 weeks (WT: 100.00±2.01 %; βB1-CTGF: 96.95±2.95%; p = 0.39; Supplementary Figure S1D).
Additionally, the ganglion cell complex, including nerve fiber layer, ganglion cell layer, and inner plexiform layer, was analyzed. The total retinal thickness of the ganglion cell complex did not differ between transgenic mice (95.18±4.42 %) and WT animals (100.00±1.72 %; p = 0.40) at 5 weeks of age. Also, at 10 weeks, no changes were detectable in βB1-CTGF animals (99.39±2.18 %) compared to WT (100.00±0.98 %; p = 0.81). The analysis of the central ganglion cell complex showed no differences in βB1-CTGF (98.34±4.60 %) and WT animals (100.00±2.69 %; p = 0.77) at 5 weeks. Also, at 10 weeks, the central thickness remained unchanged between transgenic (103.87±2.45 %) and WT mice (100.00±1.80 %; p = 0.22). Moreover, the peripheral ganglion cell complex thickness was comparable in 5-week-old βB1-CTGF animals (86.47±6.94 %) and WT mice (100.00±2.19 %; p = 0.10). At 10 weeks, the peripheral thickness remained unaltered between transgenic (95.81±2.75 %) and WT animals (100.00±1.26 %; p = 0.16; Supplementary Figure S1E).
These results show that neither the retinal function or the thickness was affected in 5- and 10-week-old βB1.CTGF mice.
3. Discussion
Glaucoma affects approximately 60 million people worldwide, making it the second most common cause of irreversible blindness [12]. To understand the underlying pathomechanisms, appropriate models are required. Currently, the most widely used glaucoma model is the DBA/2J mouse. However, DBA/2J mice develop a secondary angle-closure glaucoma initiated by iris atrophy, which occurs only in 1–1.5% of all glaucoma patients [4,13,14]. In most animal models of POAG, the IOP is increased through surgical interventions [15,16,17,18]. Often, IOP is highly elevated and the manipulations lead to local inflammations and are therefore detrimental for, e.g., analyses of the immune response. Hence, it would be beneficial to have a mouse model that reflects the pathogenesis of POAG as closely as possible. It is known that an important difference between glaucomatous and healthy eyes is the higher amount of active transforming growth factor in the extracellular matrix [12,19,20]. Due to this fact, Junglas et al. generated a transgenic mouse model that simulates POAG by overexpressing CTGF, leading to optic nerve degeneration [7]. These mice had a mixed FVB/NxCD1 background and were subsequently backcrossed into a pure CD1 background. This was done since the optic nerves of CD1 mice are more susceptible for IOP alterations [9,10]. In these mice, we observed in a previous study that the βB1-CTGF mouse model showed an increased IOP, decreased a- and b-wave amplitudes via ERG, less RGCs, a macroglia activation, and fewer cone bipolar cells in 15-week-old animals [11].
In the current study, we examined apoptosis and synaptic alterations in these βB1-CTGF mice. With regard to apoptotic mechanisms, we noted more cleaved caspase 3+ apoptotic RGCs in βB1-CTGF eyes as well as an upregulation of Casp3 mRNA levels. Moreover, TUNEL staining revealed more apoptotic cells in the ganglion cell layer of transgenic mice at 5 and 10 weeks of age. In an experimental autoimmune glaucoma (EAG) model, a higher number of caspase 3+ cells was observed 14 days after induction, while a significant loss of RGCs occurred after 22 days IOP-independently [21]. Furthermore, in other ocular hypertension (OHT) studies, apoptosis was observed via activation of the caspase pathway in the retina. For example, more cleaved caspase 3+ cells could be detected in 5-month-old DBA/2J mice and a RGC loss was detected at 9 months [22]. This timeline, apoptosis followed by RGC loss, is in accordance with our results.
Furthermore, the mRNA levels of Bax/Bcl2 were significantly upregulated in 10-week-old βB1-CTGF mice. BAX is a proapoptotic member of the BCL2 family and plays a major role in mitochondrial-mediated apoptosis in different neuronal cells [23,24]. It was shown that deficiency of BAX prevented RGC degeneration in DBA/2J mice [25]. These results lead to the assumption that retinal degeneration occurred through apoptosis in these models. Additionally, in glaucoma patients, studies indicate that RGCs die via apoptotic pathways [26].
We further investigated RGCs and neurofilament H via immunohistology and RT-qPCR analyses. We could see similar RGC numbers and Pou4f1 mRNA expression levels in βB1-CTGF animals compared to in WT at 5 and 10 weeks, while a significant downregulation of Tubb3 mRNA could be revealed in 10-week-old transgenic mice. Furthermore, we observed significantly decreased neurofilament H staining in 10-week-old βB1-CTGF animals. We assume that axonal changes occur before a loss of RGC cell bodies, which is observed in 15-week-old transgenic mice [11]. In a study using focal ischemia in pig eyes, the authors observed that neurofilament H was one of the earliest cytoskeleton subunits that underwent change [27].
Hence, in βB1-CTGF mice, early apoptosis triggers subsequent cell loss, which not only is similar to the progression in DBA/2J mice but has also some similarities to progressive damage in patients. In glaucoma patients, RGC death and visual field loss are known to occur slowly over time and apoptosis is revealed as an early marker of this disease [3,4,6,28].
The response of RGCs to visual stimuli is a result of signal integration from all cell compartments, namely cell body, axon, dendrites, and synaptic terminals [29]. However, only a few studies analyzed the role of synapses in glaucoma. In the EAG model, a loss of RGCs was observed, which was accompanied by degeneration of the presynaptic active zone protein bassoon and the postsynaptic protein PSD-95 28 days after immunization [30]. Furthermore, mice immunized with an optic nerve homogenate displayed fewer glutamatergic and GABAergic synapses after 6 weeks [31]. In DBA/2J mice, a loss of synaptic contacts was found in an aged-related manner. Fernandez-Sanchez et al. observed an absence of Vglut1 immunoreactivity in photoreceptor ribbons in 16-month-old mice [32]. In our study presented here, we noted a decrease in the gephyrin+ signal intensity in transgenic animals at 5 weeks. Interestingly, at 10 weeks, the intensity of gephyrin reverted to the WT level although a downregulation of the corresponding gene was observed via RT-qPCR.
In Alzheimer’s disease, not only does neuronal degeneration occur but also another hallmark is a loss of synapses [33,34]. It is known that, at first, neuronal and synaptic dysfunction is detectable, which triggers a compensatory response of synapses to maintain synaptic connectivity. New synapses are formed, and the remaining synapses gain size [35,36,37]. Secondly, cycles of aberrant sprouting and neuritic disorganization lead to synapse loss and neurodegeneration [35,38,39]. Additionally, in an OHT glaucoma model, synaptic vesicle proteins first increased one week after IOP elevation and, then, the total number of ribbon synapses decreased after 8 weeks. However, the authors observed immature and newly formed ribbon synapses via electron microscopy, indicating compensatory mechanisms to restore synaptic connections [40]. We therefore assume that similar mechanisms could also occur in regard to GABAergic synapses in our model. The increase in synaptic proteins could be used as compensatory factors to maintain visual integrity. In contrast to gephyrin, Vglut1 intensity was decreased at both investigated ages in βB1-CTGF mice. Vglut1 in the retina is necessary for synaptic signaling of visual-evoked responses from photoreceptors cells [41]. In diabetic rat retinae, a downregulation of Vglut1 was detected on protein as well as gene levels [42]. In the EAG model, a downregulation of Slc1717 mRNA levels could be revealed 6 weeks after immunization [31]. The loss of Vglut1 intensity might indicate changes in the transmission of signals. However, more investigations are needed to gain additional information about synaptic dysfunction in this model.
We also investigated other cell types in the retina, bipolar cells, and photoreceptors to examine whether they are affected in this model. To detect the number of bipolar cells, we used PKCα, which plays an important role in the modulation of aqueous outflow facility [43], as a rod bipolar cell marker and recoverin as a cone bipolar cell marker [44]. The numbers of rod and cone bipolar cells as well as the corresponding mRNA levels remained unchanged in 5- and 10-week-old βB1-CTGF mice. At 15 weeks of age, a diminished amount of cone bipolar cells could be noted in this model [11]. Studies using the DBA/2J mice demonstrated similar results regarding the loss of bipolar cells at young ages. Here, the first decline in bipolar cells occurred after 3 months [32,45].
Regarding investigations of photoreceptors, we could not note any difference in rods and L-cones between βB1-CTGF and wildtype mice at the age of 5 and 10 weeks. It is known that photoreceptors are eventually affected by chronically elevated IOP [46]. While some studies show that the cone density of glaucoma patients does not differ significantly from healthy eyes [47,48], cone photoreceptors seem to be affected in advanced cases of glaucoma [49]. In DBA/2J mice, degeneration of photoreceptors at 3 months was noted [32], while in an OHT rat model, animals developed a loss of cones after only 4 weeks [50]. This could be explained by the different methods of inducing ocular hypertension. In this case, they used laser coagulation of the trabecular meshwork, the perilimbal, and episcleral vessels, which induces more damage compared to a nonsurgical method. In the βB1-CTGF mouse model, where IOP increases gradually over time, the photoreceptors seem to not be affected at young ages, making it a useful model to study the slowly progressing glaucoma damage.
In glaucoma, macroglia show a reactive and not proliferative response causing remodeling processes [51,52,53]. Hence, we used anti-GFAP and anti-glutamine synthetase antibodies as astrocyte and Müller glia markers to detect possible gliosis. It is known that glutamine synthetase is overexpressed in aqueous humor of glaucoma patients [54]. In our study, we did not see gliosis after 5 and 10 weeks. In a previous study, activation of macroglia was seen in older βB1-CTGF mice (15 weeks old) [11]. In addition, in DBA/2J mice, a gliosis could not be detected until 3 months of age [51,55]. In a rat OHT study, Müller cell gliosis was observable after only one week [56]. Nonetheless, it is difficult to compare these results with ours, since early macrogliosis could be caused by the surgical intervention in these rats. In contrast, damage in the DBA/2J as well as the βB1-CTGF model occurs without surgical procedures. However, not only in animal studies but also in glaucoma patients, macrogliosis is detectable. Ashimatey et al. noted hyperreflective structures in the OCT of glaucoma patients, which were presumed to be activated astrocytes and Müller cells [57]. Furthermore, patients with a high number of retinal astrocytes and Müller cells revealed lower retinal sensitivity and reduced nerve fiber thickness in an advanced POAG disease stage [58]. In contrast, healthy persons did not show any activation of macroglia [59]. Therefore, these studies presume that activated astrocytes and Müller cells could be a clinical sign for advanced stages of POAG, but not for early ones. In addition, in βB1-CTG mice, astrogliosis seems to occur only in advanced stages, when RGC loss is noted [11].
4. Materials and Methods
4.1. Animals
All procedures concerning animals adhered to the ARVO statement for the use of animals in ophthalmic and vision research. All experiments involving animals were approved by the animal care committee of North Rhine-Westphalia, Germany (approval codes: 84-02.04.2013.A291 and 81-02.04.218.A071). Mice were kept under environmentally controlled conditions with free access to chow and water.
The used transgenic βB1-CTGF and WT mice in this study had a CD1 background [11]. The WT CD1 mice for breeding were obtained from Charles River (Sulzfeld, Germany), while the βB1-CTGF mice for breeding were kindly provided by Prof. Dr. Fuchshofer (University Regensburg, Germany). Then, all animals for this study were bred and housed at the animal facility at the Ruhr-University Bochum (Bochum, Germany). Potential βB1-CTGF mice were screened by isolating genomic DNA from tail biopsies and testing for transgenic sequenced by PCR using the following primer sequences: 5′-GGAAGTGCCAGCTCATCAGT-3’ and 5´- GTGCGGGACAGAAACCTG-3´. 5- and 10-week-old female and male mice were included in the study.
4.2. Optical Coherence Tomography
Mice were anesthetized with ketamine (120 mg/kg) and xylazine (16 mg/kg). SD-OCT images were captured using Spectralis HRA + OCT (Heidelberg Engineering GmbH, Heidelberg, Germany) in 5- and 10-week-old βB1-CTGF and WT mice (n = 6–8 animals/group) [60,61]. To measure the retinal thickness, central and peripheral images were taken with a 30-degree OCT field. The total retinal thickness as well as the thickness of the ganglion cell complex (nerve fiber layer, ganglion cell layer, and inner plexiform layer) was measured in an axis perpendicular to the individual layers using ImageJ software (NIH; Bethesda, MD, USA). Seven measurements were used to calculate the mean value for each eye [62]. At the end, the means of both groups were compared for the central and peripheral parts of the retina as well as for the total retina thickness.
4.3. Electroretinogram Analyses
For ERG measurements, mice were dark adapted overnight. The retinal function was monitored using full-field-flash electroretinography (HMsERG system, OcuScience, Henderson, NV, USA) in 5- and 10-week-old mice of both groups (n = 6–8 animals/group) [11]. The mice were anesthetized with a ketamine/xylazine cocktail (120/16 mg/kg), and their eyes were dilated with tropicamide (5%) and topically anesthetized using conjuncain (Bausch&Lomb, Berlin, Germany). Body temperature was maintained at 37 °C with a feedback temperature controller (TC-1000; CWE Inc., Ardmore, PA, USA). Reference electrodes were placed subcutaneously below the right and left ears, and a ground electrode was placed at the base of the tail. Contact lenses with silver thread recording electrodes were placed in the center of the cornea after the application of methocel (Omni Vision, Puchheim, Germany). Before measurement, the electroretinography equipment was covered with a Faraday cage. Scotopic flash ERGs were recorded at 0.1, 0.3, 1, 3, 10, and 25 cd/m2. The signals obtained from the corneal surface were amplified, digitized, averaged, and stored using commercial software (ERGView 4.380R; OcuScience). A 50 Hz filtering of the data was applied before evaluating the amplitude of the a- and b-waves.
4.4. Tissue Preparation for Immunohistology
After 5 and 10 weeks, mice eyes were enucleated and fixed in 4% paraformaldehyde for 1 h. Thereafter, the eyes underwent a 10% sucrose treatment and were embedded in a Neg-50 compound (Tissue-Tek; Fisher Scientific, Schwerte, Germany). Ten micrometer thick cross sections were cut with a cryostat (Fisher Scientific) for further staining [63].
4.5. Immunohistology
In order to identify different retinal cell types, specific immunofluorescence antibodies were applied (n = 5–9 eyes/group; 6 sections/animal, Table 1) [64]. Briefly, retinal cross sections were blocked with a solution containing 10–20% donkey, 2–3% bovine serum albumin, and/or goat serum and 0.1% Triton-X in PBS. The sections were incubated with primary antibodies at room temperature overnight. Incubation using corresponding secondary antibodies was performed for 1 h on the next day. For the detection of apoptotic cells, a commercially available TUNEL Kit (In Situ Cell Death Detection Kit; Roche; Sigma-Aldrich, St. Louis, MO, USA) was used according to the manufacturer’s instructions. Nuclear staining with 4′,6 diamidino-2-phenylindole (DAPI, Serva Electrophoresis, Heidelberg, Germany) was included to facilitate orientation on the slides. Negative controls were performed for each stain by using secondary antibodies only.
Table 1.
Primary Antibodies | Secondary Antibodies | ||||
---|---|---|---|---|---|
Antibody | Company | Dilution | Antibody | Company | Dilution |
Anti-Brn3a | Santa Cruz | 1:100 | Donkey anti-goat Alexa Fluor 488 | Dianova | 1:500 |
Anti-cleaved caspase 3 | Sigma-Aldrich | 1:300 | Donkey anti-rabbit Alexa Fluor 555 | Invitrogen | 1:500 |
Anti-gephyrin | Synaptic Systems | 1:500 | Donkey anti-rabbit Alexa Fluor 488 | Thermo Fisher | 1:500 |
Anti-GFAP | Millipore | 1:500 | Donkey anti-chicken Cy3 | Millipore | 1:500 |
Anti-glutamine synthetase | Abcam | 1:500 | Goat anti-mouse Alexa Fluor 488 | Invitrogen | 1:500 |
Anti-neurofilament H | Synaptic Systems | 1:500 | Donkey anti-chicken Cy3 | Millipore | 1:500 |
Anti-opsin | Millipore | 1:1200 | Donkey anti-rabbit Alexa Fluor 555 | Invitrogen | 1:500 |
Anti-PKCα | Santa Cruz | 1:300 | Goat anti-mouse Alexa Fluor 488 | Invitrogen | 1:500 |
Anti-rhodopsin | Abcam | 1:400 | Goat anti-mouse Alexa Fluor 488 | Eugene | 1:500 |
Anti-ribeye | Synaptic Systems | 1:500 | Donkey anti-guinea pig Alexa Fluor 488 | Jackson Immuno Research | 1:500 |
Anti-recoverin | Millipore | 1:1000 | Donkey anti-rabbit A555 | Invitrogen | 1:400 |
Anti-Vglut1 | Synaptic Systems | 1:500 | Donkey anti-chicken Cy3 | Millipore | 1:500 |
Anti-rhodopsin | Abcam | 1:400 | Goat anti-mouse Alexa Fluor 488 | Eugene | 1:500 |
4.6. Histological Examination
The photographs were taken using a fluorescence microscope (Axio Imager M1 or M2, Zeiss, Jena, Germany). Two photos of the peripheral and two of the central part of each section were captured at distances 300 and 3100 µm dorsal and ventral to the optic nerve for each retinal cross section (6 sections/eye, n = 5–9 eyes/group) [30,65]. The images were transferred to Corel Paint Shop Pro (V13, Corel Corporation, Ottawa, ONT, Canada) and equal excerpts of 800 × 600 pixel (respectively, 700 × 300 pixel for neurofilament H) were cut out. Afterwards, Brn-3a+, PKCα+, opsin+, and TUNEL+ cells were counted in a masked fashion using ImageJ software [11]. Regarding GFAP, glutamine synthetase, rhodopsin, recoverin, and neurofilament H, the percentage of stained area was analyzed using ImageJ software. With regard to gephyrin and Vglut1 staining, the staining intensity was evaluated. For both ImageJ analyses, the images were transformed into grayscale. To minimize interference with background labeling, a defined rolling ball radius was subtracted (Table 2). Then, for each picture, suitable lower and upper thresholds were defined. The ideal values were obtained when the grayscale picture corresponded to the original one. Once the thresholds from all pictures were set, the mean value for the lower threshold was calculated, and this number was used for final analyses. The percentage (respectively, the intensity) of the stained area was then measured between these defined threshold (Table 2) [63,66].
Table 2.
Protein | Background | Lower Threshold | Upper Threshold |
---|---|---|---|
Gephyrin | 50 | 6.01 | 252.22 |
GFAP | 50 | 8.97 | 246.72 |
Glutamine synthetase | 50 | 10.47 | 262.82 |
Neurofilament H | 50 | 10.22 | 84.63 |
Recoverin | 50 | 9.95 | 264.02 |
Rhodopsin | 50 | 9.02 | 265.00 |
Vglut1 | 50 | 6.62 | 250.29 |
4.7. Quantitative Real-Time PCR
Both retinae of each animal (n = 5–7 animals/group) were pooled for RNA preparation and cDNA synthesis as previously described [11]. The designed oligonucleotides for RT-qPCR are shown in Table 3. Βeta-actin (Actb) and cyclophilin (Ppid) served as reference genes. The RT-qPCR was performed using DyNAmo Flash SYBR Green (Fisher Scientific) on the PikoReal RT-qPCR Cycler (Fisher Scientific) [67,68]. The values were transferred to REST© software (Qiagen, Hilden, Germany) for further analysis.
Table 3.
Gene | Forward (F) and Reverse (R) Oligonucleotides | GenBank Accession Number | Amplicon Size |
---|---|---|---|
Actb-F Actb-R |
ctaaggccaaccgtgaaag accagaggcatacagggaca |
NM_007393.5 | 104 bp |
Bax-F Bax-R |
gtgagcggctgcttgtct gtgggggtcccgaagtag |
NM_007527.3 | 73 bp |
Bcl2-F Bcl2-R |
agtacctgaaccggcatctg ggggccatatagttccacaaa |
NM_009741.5 | 77 bp |
Casp3-F Casp3-R |
gaggctgacttcctgtatgctt aaccacgacccgtccttt |
NM_001284409.1 | 77 bp |
Gphn-F Gphn-R |
tgatcttcatgctcagatcca ttgcaaatgttgttggcaag |
NM_145965.2 | 68 bp |
Nefh-F Nefh-R |
cattgagattgccgcttaca actcggaccaaagccaatc |
NM_010904.3 | 67 bp |
Pou4f1-F Pou4f1-R |
ctccctgagcacaagtaccc ctggcgaagaggttgctc |
AY706205.1 | 98 bp |
Ppid-F Ppid-R |
ttcttcataaccacaagtcaagacc tccacctccgtaccacatc |
M60456.1 | 95 bp |
Prkca-F Prkca-R |
caagggatgaaatgtgacacc cctcttctctgtgtgatccattc |
NM_011101.3 | 96 bp |
Rcvrn-F Rcvrn-R |
caatgggaccatcagcaaa cctaggcttgatcattttga |
NM_009038.2 | 71 bp |
Rho-F Rho-R |
tgtggtcttcacctggatcat gaacattgcatgccctcag |
NM_145383.1 | 90 bp |
Slc17a7-F Slc17a7-R |
gtgcaatgaccaaggacaag agatgacaccgccgtagtg |
NM_182993.2 | 103 bp |
Slc18a3-F Slc18a3-R |
agagccctaccctgatctctg caagtaggcgctggcattag |
NM_021712.3 | 77 bp |
4.8. Statistics
SD-OCT, ERG, and immunohistological data are presented as mean ± SEM. The βB1-CTGF animals were compared to the WT group via two-tailed Student’s t-test using Statistica Software (Version 13, Dell, Tulsa, OK, USA). For SD-OCT and immunohistology, the WT values were set to 100%. Cleaved caspase 3+ and TUNEL+ cells are displayed as cells/mm. Regarding RT-qPCR, the relative expression values are presented as median ± quartile + minimum/maximum and were assessed via Pair Wise Fixed Reallocation Randomization Test© using REST© software (Qiagen) [69]. p-values below 0.05 were considered statistically significant, with * p < 0.05, ** p < 0.01, and *** p < 0.001.
5. Conclusions
With this study, we investigated apoptotic mechanisms and synapses in a βB1-CTGF mouse model. We noted more apoptotic RGCs, which was followed by a loss of neurofilament H. This slow progressive degeneration mimics the situation in glaucoma patients. Hence, the results underline that βB1-CTGF mice serve as a suitable model to study neurodegeneration occurring in POAG in more detail.
Supplementary Materials
The following are available online at https://www.mdpi.com/1422-0067/22/4/1997/s1, Figure S1: No functional or morphological alterations.
Author Contributions
Conceptualization, S.R. and S.C.J.; formal Analysis, M.W. and S.R.; methodology, M.W., S.R., A.M.M.-B., J.D.D., R.F., G.S., H.B.D., and S.C.J.; investigation, M.W., S.R., A.M.M.-B., J.D.D., and G.S.; resources, S.C.J.; writing—original draft preparation, M.W. and S.R.; writing—review and editing, A.M.M.-B., J.D.D., R.F., H.B.D., and S.C.J.; visualization, M.W., S.R., and S.C.J.; supervision, S.R. and S.C.J.; project administration, S.R. and S.C.J.; funding acquisition, S.R., M.W., and S.C.J. All authors have read and agreed to the published version of the manuscript.
Funding
This study was in part supported by FoRUM (Ruhr-University Bochum, Germany) and the Ernst and Berta Grimmke foundation (Germany). MW was supported by Verein Glück im Blick (Bochum, Germany).
Institutional Review Board Statement
All experiments involving animals were approved by the animal care committee of North Rhine-Westphalia, Germany (approval codes: 84-02.04.2013.A291 and 81-02.04.218.A071).
Informed Consent Statement
Not applicable.
Data Availability Statement
Data sharing not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Flaxman S.R., Bourne R.R.A., Resnikoff S., Ackland P., Braithwaite T., Cicinelli M.V., Das A., Jonas J.B., Keeffe J., Kempen J.H., et al. Global causes of blindness and distance vision impairment 1990–2020: A systematic review and meta-analysis. Lancet Global Health. 2017;5:e1221–e1234. doi: 10.1016/S2214-109X(17)30393-5. [DOI] [PubMed] [Google Scholar]
- 2.Tezel G., Wax M.B. Glaucoma. Chem. Immunol. Allergy. 2007;92:221–227. doi: 10.1159/000099273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kerrigan-Baumrind L.A., Quigley H.A., Pease M.E., Kerrigan D.F., Mitchell R.S. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest. Ophthalmol. Vis. Sci. 2000;41:741–748. [PubMed] [Google Scholar]
- 4.EGS European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition—Chapter 2: Classification and Terminology. Br. J. Ophthalmol. 2017;101:73–127. doi: 10.1136/bjophthalmol-2016-EGSguideline.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Harwerth R.S., Wheat J.L., Fredette M.J., Anderson D.R. Linking structure and function in glaucoma. Prog. Retin Eye Res. 2010;29:249–271. doi: 10.1016/j.preteyeres.2010.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Quigley H.A. Glaucoma. Lancet. 2011;377:1367–1377. doi: 10.1016/S0140-6736(10)61423-7. [DOI] [PubMed] [Google Scholar]
- 7.Junglas B., Kuespert S., Seleem A.A., Struller T., Ullmann S., Bosl M., Bosserhoff A., Kostler J., Wagner R., Tamm E.R., et al. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. Am. J. Pathol. 2012;180:2386–2403. doi: 10.1016/j.ajpath.2012.02.030. [DOI] [PubMed] [Google Scholar]
- 8.Sommer A., Tielsch J.M., Katz J., Quigley H.A., Gottsch J.D., Javitt J., Singh K. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol. 1991;109:1090–1095. doi: 10.1001/archopht.1991.01080080050026. [DOI] [PubMed] [Google Scholar]
- 9.Schaub J.A., Kimball E.C., Steinhart M.R., Nguyen C., Pease M.E., Oglesby E.N., Jefferys J.L., Quigley H.A. Regional Retinal Ganglion Cell Axon Loss in a Murine Glaucoma Model. Invest. Ophthalmol. Vis. Sci. 2017;58:2765–2773. doi: 10.1167/iovs.17-21761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Steinhart M.R., Cone-Kimball E., Nguyen C., Nguyen T.D., Pease M.E., Chakravarti S., Oglesby E.N., Quigley H.A. Susceptibility to glaucoma damage related to age and connective tissue mutations in mice. Exp. Eye Res. 2014;119:54–60. doi: 10.1016/j.exer.2013.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Reinehr S., Koch D., Weiss M., Froemel F., Voss C., Dick H.B., Fuchshofer R., Joachim S.C. Loss of retinal ganglion cells in a new genetic mouse model for primary open-angle glaucoma. J. Cell. Mol. Med. 2019 doi: 10.1111/jcmm.14433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wallace D.M., Murphy-Ullrich J.E., Downs J.C., O’Brien C.J. The role of matricellular proteins in glaucoma. Matrix Biol. 2014;37:174–182. doi: 10.1016/j.matbio.2014.03.007. [DOI] [PubMed] [Google Scholar]
- 13.John S.W., Smith R.S., Savinova O.V., Hawes N.L., Chang B., Turnbull D., Davisson M., Roderick T.H., Heckenlively J.R. Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest. Ophthalmol. Vis. Sci. 1998;39:951–962. [PubMed] [Google Scholar]
- 14.Yang J.W., Sakiyalak D., Krupin T. Pigmentary glaucoma. J. Glaucoma. 2001;10(Suppl 1):S30–S32. doi: 10.1097/00061198-200110001-00012. [DOI] [PubMed] [Google Scholar]
- 15.Levkovitch-Verbin H., Quigley H.A., Martin K.R., Valenta D., Baumrind L.A., Pease M.E. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest. Ophthalmol. Vis. Sci. 2002;43:402–410. [PubMed] [Google Scholar]
- 16.Sappington R.M., Carlson B.J., Crish S.D., Calkins D.J. The microbead occlusion model: A paradigm for induced ocular hypertension in rats and mice. Invest. Ophthalmol. Vis. Sci. 2010;51:207–216. doi: 10.1167/iovs.09-3947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mirzaei M., Gupta V.K., Chitranshi N., Deng L., Pushpitha K., Abbasi M., Chick J.M., Rajput R., Wu Y., McKay M.J., et al. Retinal proteomics of experimental glaucoma model reveal intraocular pressure-induced mediators of neurodegenerative changes. J. Cell. Biochem. 2020 doi: 10.1002/jcb.29822. [DOI] [PubMed] [Google Scholar]
- 18.Lakshmanan Y., Wong F.S.Y., Zuo B., Bui B.V., Chan H.H. Longitudinal outcomes of circumlimbal suture model-induced chronic ocular hypertension in Sprague-Dawley albino rats. Graefes Arch. Clin. Exp. Ophthalmol. 2020 doi: 10.1007/s00417-020-04820-7. [DOI] [PubMed] [Google Scholar]
- 19.Taylor A.W. Primary Open-Angle Glaucoma: A Transforming Growth Factor-β Pathway-Mediated Disease. Am. J. Pathol. 2012;180:2201–2204. doi: 10.1016/j.ajpath.2012.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Wallace D.M., Pokrovskaya O., O’Brien C.J. The Function of Matricellular Proteins in the Lamina Cribrosa and Trabecular Meshwork in Glaucoma. J. Ocul. Pharmacol. Ther. 2015;31:386–395. doi: 10.1089/jop.2014.0163. [DOI] [PubMed] [Google Scholar]
- 21.Joachim S.C., Mondon C., Gramlich O.W., Grus F.H., Dick H.B. Apoptotic retinal ganglion cell death in an autoimmune glaucoma model is accompanied by antibody depositions. J. Mol. Neurosci. 2014;52:216–224. doi: 10.1007/s12031-013-0125-2. [DOI] [PubMed] [Google Scholar]
- 22.Zhou X., Li F., Kong L., Tomita H., Li C., Cao W. Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma. J. Biol. Chem. 2005;280:31240–31248. doi: 10.1074/jbc.M502641200. [DOI] [PubMed] [Google Scholar]
- 23.Mosinger Ogilvie J., Deckwerth T.L., Knudson C.M., Korsmeyer S.J. Suppression of developmental retinal cell death but not of photoreceptor degeneration in Bax-deficient mice. Invest. Ophthalmol. Vis. Sci. 1998;39:1713–1720. [PubMed] [Google Scholar]
- 24.Deckwerth T.L., Elliott J.L., Knudson C.M., Johnson E.M., Jr., Snider W.D., Korsmeyer S.J. BAX is required for neuronal death after trophic factor deprivation and during development. Neuron. 1996;17:401–411. doi: 10.1016/S0896-6273(00)80173-7. [DOI] [PubMed] [Google Scholar]
- 25.Libby R.T., Li Y., Savinova O.V., Barter J., Smith R.S., Nickells R.W., John S.W. Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet. 2005;1:17–26. doi: 10.1371/journal.pgen.0010004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Kerrigan L.A., Zack D.J., Quigley H.A., Smith S.D., Pease M.E. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch. Ophthalmol. 1997;115:1031–1035. doi: 10.1001/archopht.1997.01100160201010. [DOI] [PubMed] [Google Scholar]
- 27.Balaratnasingam C., Morgan W.H., Bass L., Kang M., Cringle S.J., Yu D.Y. Time-dependent effects of focal retinal ischemia on axonal cytoskeleton proteins. Invest. Ophthalmol. Vis. Sci. 2010;51:3019–3028. doi: 10.1167/iovs.09-4692. [DOI] [PubMed] [Google Scholar]
- 28.Cordeiro M.F., Guo L., Luong V., Harding G., Wang W., Jones H.E., Moss S.E., Sillito A.M., Fitzke F.W. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc. Natl. Acad. Sci. USA. 2004;101:13352–13356. doi: 10.1073/pnas.0405479101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Morquette J.B., Di Polo A. Dendritic and synaptic protection: Is it enough to save the retinal ganglion cell body and axon? J. Neuroophthalmol. 2008;28:144–154. doi: 10.1097/WNO.0b013e318177edf0. [DOI] [PubMed] [Google Scholar]
- 30.Reinehr S., Kuehn S., Casola C., Koch D., Stute G., Grotegut P., Dick H.B., Joachim S.C. HSP27 immunization reinforces AII amacrine cell and synapse damage induced by S100 in an autoimmune glaucoma model. Cell Tissue Res. 2018;371:237–249. doi: 10.1007/s00441-017-2710-0. [DOI] [PubMed] [Google Scholar]
- 31.Reinehr S., Reinhard J., Wiemann S., Hesse K., Voss C., Gandej M., Dick H.B., Faissner A., Joachim S.C. Transfer of the Experimental Autoimmune Glaucoma Model from Rats to Mice-New Options to Study Glaucoma Disease. Int. J. Mol. Sci. 2019;20:2563. doi: 10.3390/ijms20102563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Fernandez-Sanchez L., de Sevilla Muller L.P., Brecha N.C., Cuenca N. Loss of outer retinal neurons and circuitry alterations in the DBA/2J mouse. Investig. Ophthalmol. Vis. Sci. 2014;55:6059–6072. doi: 10.1167/iovs.14-14421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Tonnies E., Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease. J. Alzheimer Dis. JAD. 2017;57:1105–1121. doi: 10.3233/JAD-161088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–421. doi: 10.1016/S0896-6273(03)00434-3. [DOI] [PubMed] [Google Scholar]
- 35.Jansen D., Janssen C.I., Vanmierlo T., Dederen P.J., van Rooij D., Zinnhardt B., Nobelen C.L., Janssen A.L., Hafkemeijer A., Mutsaers M.P., et al. Cholesterol and synaptic compensatory mechanisms in Alzheimer’s disease mice brain during aging. J. Alzheimer Dis. JAD. 2012;31:813–826. doi: 10.3233/JAD-2012-120298. [DOI] [PubMed] [Google Scholar]
- 36.Scheff S.W., Price D.A. Synaptic pathology in Alzheimer’s disease: A review of ultrastructural studies. Neurobiol. Aging. 2003;24:1029–1046. doi: 10.1016/j.neurobiolaging.2003.08.002. [DOI] [PubMed] [Google Scholar]
- 37.Boncristiano S., Calhoun M.E., Howard V., Bondolfi L., Kaeser S.A., Wiederhold K.H., Staufenbiel M., Jucker M. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol. Aging. 2005;26:607–613. doi: 10.1016/j.neurobiolaging.2004.06.010. [DOI] [PubMed] [Google Scholar]
- 38.Arendt T. Alzheimer’s disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience. 2001;102:723–765. doi: 10.1016/S0306-4522(00)00516-9. [DOI] [PubMed] [Google Scholar]
- 39.Masliah E., Crews L., Hansen L. Synaptic remodeling during aging and in Alzheimer’s disease. J. Alzheimer Dis. JAD. 2006;9(Suppl. 3):91–99. doi: 10.3233/JAD-2006-9S311. [DOI] [PubMed] [Google Scholar]
- 40.Park H.Y., Kim J.H., Park C.K. Alterations of the synapse of the inner retinal layers after chronic intraocular pressure elevation in glaucoma animal model. Mol. Brain. 2014;7:53. doi: 10.1186/s13041-014-0053-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Johnson J., Fremeau R.T., Jr., Duncan J.L., Renteria R.C., Yang H., Hua Z., Liu X., LaVail M.M., Edwards R.H., Copenhagen D.R. Vesicular glutamate transporter 1 is required for photoreceptor synaptic signaling but not for intrinsic visual functions. J. Neurosci. 2007;27:7245–7255. doi: 10.1523/JNEUROSCI.0815-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Ly A., Scheerer M.F., Zukunft S., Muschet C., Merl J., Adamski J., de Angelis M.H., Neschen S., Hauck S.M., Ueffing M. Retinal proteome alterations in a mouse model of type 2 diabetes. Diabetologia. 2014;57:192–203. doi: 10.1007/s00125-013-3070-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Khurana R.N., Deng P.F., Epstein D.L., Vasantha Rao P. The role of protein kinase C in modulation of aqueous humor outflow facility. Exp. Eye Res. 2003;76:39–47. doi: 10.1016/S0014-4835(02)00255-5. [DOI] [PubMed] [Google Scholar]
- 44.Milam A.H., Dacey D.M., Dizhoor A.M. Recoverin immunoreactivity in mammalian cone bipolar cells. Vis. Neurosci. 1993;10:1–12. doi: 10.1017/S0952523800003175. [DOI] [PubMed] [Google Scholar]
- 45.Moon J.I., Kim I.B., Gwon J.S., Park M.H., Kang T.H., Lim E.J., Choi K.R., Chun M.H. Changes in retinal neuronal populations in the DBA/2J mouse. Cell. Tissue Res. 2005;320:51–59. doi: 10.1007/s00441-004-1062-8. [DOI] [PubMed] [Google Scholar]
- 46.Nork T.M., Ver Hoeve J.N., Poulsen G.L., Nickells R.W., Davis M.D., Weber A.J., Vaegan, Sarks S.H., Lemley H.L., Millecchia L.L. Swelling and loss of photoreceptors in chronic human and experimental glaucomas. Arch. Ophthalmol. 2000;118:235–245. doi: 10.1001/archopht.118.2.235. [DOI] [PubMed] [Google Scholar]
- 47.Matlach J., Mulholland P.J., Cilkova M., Chopra R., Shah N., Redmond T., Dakin S.C., Garway-Heath D.F., Anderson R.S. Relationship between Psychophysical Measures of Retinal Ganglion Cell Density and In Vivo Measures of Cone Density in Glaucoma. Ophthalmology. 2017;124:310–319. doi: 10.1016/j.ophtha.2016.10.029. [DOI] [PubMed] [Google Scholar]
- 48.Hasegawa T., Ooto S., Takayama K., Makiyama Y., Akagi T., Ikeda H.O., Nakanishi H., Suda K., Yamada H., Uji A., et al. Cone Integrity in Glaucoma: An Adaptive-Optics Scanning Laser Ophthalmoscopy Study. Am. J. Ophthalmol. 2016;171:53–66. doi: 10.1016/j.ajo.2016.08.021. [DOI] [PubMed] [Google Scholar]
- 49.Vincent A., Shetty R., Devi S.A., Kurian M.K., Balu R., Shetty B. Functional involvement of cone photoreceptors in advanced glaucoma: A multifocal electroretinogram study. Doc. Ophthalmol. 2010;121:21–27. doi: 10.1007/s10633-010-9227-0. [DOI] [PubMed] [Google Scholar]
- 50.Ortin-Martinez A., Salinas-Navarro M., Nadal-Nicolas F.M., Jimenez-Lopez M., Valiente-Soriano F.J., Garcia-Ayuso D., Bernal-Garro J.M., Aviles-Trigueros M., Agudo-Barriuso M., Villegas-Perez M.P., et al. Laser-induced ocular hypertension in adult rats does not affect non-RGC neurons in the ganglion cell layer but results in protracted severe loss of cone-photoreceptors. Exp. Eye Res. 2015;132:17–33. doi: 10.1016/j.exer.2015.01.006. [DOI] [PubMed] [Google Scholar]
- 51.Inman D.M., Horner P.J. Reactive nonproliferative gliosis predominates in a chronic mouse model of glaucoma. Glia. 2007;55:942–953. doi: 10.1002/glia.20516. [DOI] [PubMed] [Google Scholar]
- 52.Schneider M., Fuchshofer R. The role of astrocytes in optic nerve head fibrosis in glaucoma. Exp. Eye Res. 2016;142:49–55. doi: 10.1016/j.exer.2015.08.014. [DOI] [PubMed] [Google Scholar]
- 53.Seitz R., Ohlmann A., Tamm E.R. The role of Muller glia and microglia in glaucoma. Cell. Tissue Res. 2013;353:339–345. doi: 10.1007/s00441-013-1666-y. [DOI] [PubMed] [Google Scholar]
- 54.Bagnis A., Izzotti A., Centofanti M., Saccà S.C. Aqueous humor oxidative stress proteomic levels in primary open angle glaucoma. Exp. Eye Res. 2012;103:55–62. doi: 10.1016/j.exer.2012.07.011. [DOI] [PubMed] [Google Scholar]
- 55.Zhou X., Li F., Kong L., Chodosh J., Cao W. Anti-inflammatory effect of pigment epithelium-derived factor in DBA/2J mice. Mol. Vis. 2009;15:438–450. [PMC free article] [PubMed] [Google Scholar]
- 56.Ji M., Miao Y., Dong L.D., Chen J., Mo X.F., Jiang S.X., Sun X.H., Yang X.L., Wang Z. Group I mGluR-mediated inhibition of Kir channels contributes to retinal Muller cell gliosis in a rat chronic ocular hypertension model. J. Neurosci. 2012;32:12744–12755. doi: 10.1523/JNEUROSCI.1291-12.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Ashimatey B.S., King B.J., Swanson W.H. Retinal putative glial alterations: Implication for glaucoma care. Ophthalmic Physiol. Opt. J. Br. Coll. Ophthalmic Opt. 2018;38:56–65. doi: 10.1111/opo.12425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Nutzi C., Schotzau A., Grieshaber M.C. Structure and Function Relationship of Activated Retinal Glia in Primary Open-Angle Glaucoma Patients. J. Ophthalmol. 2017;2017:7043752. doi: 10.1155/2017/7043752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Grieshaber M.C., Moramarco F., Schoetzau A., Flammer J., Orguel S. Detection of retinal glial cell activation in glaucoma by time domain optical coherence tomography. Klin. Monbl. Augenheilkd. 2012;229:314–318. doi: 10.1055/s-0031-1281857. [DOI] [PubMed] [Google Scholar]
- 60.Li Y., Zhang Y., Chen S., Vernon G., Wong W.T., Qian H. Light-Dependent OCT Structure Changes in Photoreceptor Degenerative rd 10 Mouse Retina. Invest. Ophthalmol. Vis. Sci. 2018;59:1084–1094. doi: 10.1167/iovs.17-23011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Garcia Garrido M., Mühlfriedel R.L., Beck S.C., Wallrapp C., Seeliger M.W. Scale Adjustments to Facilitate Two-Dimensional Measurements in OCT Images. PLoS ONE. 2015;10:e0131154. doi: 10.1371/journal.pone.0131154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Reinehr S., Gomes S.C., Gassel C.J., Asaad M.A., Stute G., Schargus M., Dick H.B., Joachim S.C. Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model. Front. Pharmacol. 2019;10:1381. doi: 10.3389/fphar.2019.01381. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Casola C., Reinehr S., Kuehn S., Stute G., Spiess B.M., Dick H.B., Joachim S.C. Specific Inner Retinal Layer Cell Damage in an Autoimmune Glaucoma Model Is Induced by GDNF With or Without HSP27. Invest. Ophthalmol. Vis. Sci. 2016;57:3626–3639. doi: 10.1167/iovs.15-18999R2. [DOI] [PubMed] [Google Scholar]
- 64.Reinehr S., Reinhard J., Gandej M., Kuehn S., Noristani R., Faissner A., Dick H.B., Joachim S.C. Simultaneous Complement Response via Lectin Pathway in Retina and Optic Nerve in an Experimental Autoimmune Glaucoma Model. Front. Cell Neurosci. 2016;10:140. doi: 10.3389/fncel.2016.00140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Li J., Zhao L., Urabe G., Fu Y., Guo L.W. Epigenetic intervention with a BET inhibitor ameliorates acute retinal ganglion cell death in mice. Mol. Vis. 2017;23:149–159. [PMC free article] [PubMed] [Google Scholar]
- 66.Reinehr S., Reinhard J., Gandej M., Gottschalk I., Stute G., Faissner A., Dick H.B., Joachim S.C. S100B immunization triggers NFκB and complement activation in an autoimmune glaucoma model. Sci. Rep. 2018;8:9821. doi: 10.1038/s41598-018-28183-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Wilmes A.T., Reinehr S., Kuhn S., Pedreiturria X., Petrikowski L., Faissner S., Ayzenberg I., Stute G., Gold R., Dick H.B., et al. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. J. Neuroinflammation. 2018;15:183. doi: 10.1186/s12974-018-1208-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Palmhof M., Lohmann S., Schulte D., Stute G., Wagner N., Dick H.B., Joachim S.C. Fewer Functional Deficits and Reduced Cell Death after Ranibizumab Treatment in a Retinal Ischemia Model. Int. J. Mol. Sci. 2018;19:1636. doi: 10.3390/ijms19061636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36. doi: 10.1093/nar/30.9.e36. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data sharing not applicable.